Q-omics provides the consensus-scored TTC16 profile across patient tissues and cancer cell-line models. TTC16 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TTC16 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TTC16 RNA expression shows 15,981 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, COAD, and DLBC as cancer lineages where TTC16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC16 survival associations across molecular data types. TTC16 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC16 RNA expression–survival associations across cancer types. High TTC16 expression shows unfavorable associations in COAD and LGG, but favorable associations in HNSC, SKCM, BRCA and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TTC16 RNA expression.
This table summarizes TTC16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TTC16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC16 shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in COAD, KIRC and BRCA. The COAD box plot shows higher TTC16 RNA expression in tumor versus normal tissue (log2 FC = +0.252, t-test p < 0.001).
This table shows molecular features associated with TTC16 in patient tissues and cancer cell lines. In patient samples, TTC16 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
